BCG-unresponsive non-muscle-invasive bladder cancer: Recommendations from the IBCG

Ashish M. Kamat, Marc Colombel, Debasish Sundi, Donald Lamm, Andreas Boehle, Maurizio Brausi, Roger Buckley, Raj Persad, Joan Palou, Mark Soloway, J. Alfred Witjes

    Research output: Contribution to journalReview articleResearchpeer-review

    66 Citations (Scopus)


    © 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. Intravesical immunotherapy with live attenuated BCG remains the standard of care for patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Most patients initially respond, but recurrence is frequent and progression to invasive cancer is a concern. No established and effective intravesical therapies are available for patients whose tumours recur after BCG, representing a clinically important unmet need. Development and discovery of treatment options for BCG-unresponsive NMIBC is a high priority in order to decrease the morbidity, burden of health-care expenditures, and mortality related to bladder cancer. This Review of treatment options after BCG failure focuses on principles of optimal management emerging therapies, thus enabling a synthesis of recommendations for management for such patients.
    Original languageEnglish
    Pages (from-to)244-255
    JournalNature Reviews Urology
    Issue number4
    Publication statusPublished - 1 Apr 2017


    Dive into the research topics of 'BCG-unresponsive non-muscle-invasive bladder cancer: Recommendations from the IBCG'. Together they form a unique fingerprint.

    Cite this